Rx-to-OTC switch products reimbursed by 30% of HMOs -- Novartis report.
This article was originally published in The Tan Sheet
Executive Summary
Rx-TO-OTC SWITCH PRODUCT PURCHASES REIMBURSED BY 30% OF HMOs, according to the "Novartis Pharmacy Benefit Report: 1997 Trends & Forecasts." The report notes that while "almost 30% of the HMOs in this sample said they have continued to cover an Rx-to-OTC switch product after it changed status," 66% discontinue coverage for switched drugs.